🔥🐔 BizChicken 🐔🔥
Companies Similar to Inozyme Pharma, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Gain Therapeutics, Inc.
Site-Directed Enzyme Enhancement Therapy platform
Gain Therapeutics, Inc. is a biotechnology company developing therapies for diseases caused by protein misfolding, focusing on rare genetic diseases and neurological disorders. It utilizes its proprietary technology to discover and develop molecules targeting misfolded proteins.
Symbol: GANX
Recent Price: $2.18
Industry: Biotechnology
CEO: Mr. Gene Mack M.B.A.
Sector: Healthcare
Employees: 29
Address: 4800 Montgomery Lane, Bethesda, MD 20814
Phone: 301 500 1556
Last updated: 2024-12-31
Halozyme Therapeutics, Inc.
ENHANZE drug delivery technology
Halozyme Therapeutics, Inc. is a biopharma technology platform company specializing in enabling subcutaneous delivery of biologics using its patented ENHANZE technology. The company operates in the United States and internationally, offering products such as Hylenex recombinant and developing treatments for various medical conditions including lymphomas and immunodeficiency disorders.
Symbol: HALO
Recent Price: $47.99
Industry: Biotechnology
CEO: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Sector: Healthcare
Employees: 373
Address: 11388 Sorrento Valley Road, San Diego, CA 92121
Phone: 858 794 8889
Last updated: 2024-12-31
INmune Bio, Inc.
INKmune
INmune Bio, Inc. is a clinical-stage immunotherapy company focused on developing drugs to reprogram the patient's innate immune system for the treatment of hematologic malignancies, solid tumors, chronic inflammation, and Alzheimer's disease.
Symbol: INMB
Recent Price: $4.65
Industry: Biotechnology
CEO: Dr. Raymond Joseph Tesi M.D.
Sector: Healthcare
Employees: 11
Address: 225 NE Mizner Boulevard, Boca Raton, FL 33432
Phone: 858 964 3720
Last updated: 2024-12-31
Inhibrx Biosciences, Inc.
Therapeutic Candidates (INBRX-109, INBRX-106)
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.
Symbol: INBX
Recent Price: $15.14
Industry: Biotechnology
CEO: Mr. Mark Paul Lappe
Sector: Healthcare
Employees: 166
Address: 11025 North Torrey Pines Road, La Jolla, CA 92037
Phone: 858-795-4220
Last updated: 2024-12-31
Neurocrine Biosciences, Inc.
INGREZZA
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for various conditions, focusing on innovative solutions for unmet medical needs.
Symbol: NBIX
Recent Price: $137.06
Industry: Drug Manufacturers - Specialty & Generic
CEO: Mr. Kyle W. Gano Ph.D.
Sector: Healthcare
Employees: 1700
Address: 12780 El Camino Real, San Diego, CA 92130
Phone: 858 617 7600
Last updated: 2024-12-31
Oncternal Therapeutics, Inc.
zilovertamab, ONCT-216, ONCT-808, ONCT-534
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.
Symbol: ONCT
Recent Price: $0.53
Industry: Biotechnology
CEO: Dr. James B. Breitmeyer M.D., Ph.D.
Sector: Healthcare
Employees: 27
Address: 12230 El Camino Real, San Diego, CA 92130
Phone: 858 434 1113
Last updated: 2024-12-31
Reneo Pharmaceuticals, Inc.
REN001
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.
About | About | About | Management | Directors | Contact | Contact | Careers | Careers | About | About | About
Symbol: RPHM
Recent Price: $18.20
Industry: Biotechnology
CEO: Mr. Gregory J. Flesher
Sector: Healthcare
Employees: 8
Address: 18575 Jamboree Road, Irvine, CA 92612
Phone: 619 733 3852
Last updated: 2024-12-31
Sarepta Therapeutics, Inc.
EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.
Contact | About | Leadership | About | About | About | Locations | About | About | About | About
Symbol: SRPT
Recent Price: $121.19
Industry: Biotechnology
CEO: Mr. Douglas S. Ingram Esq.
Sector: Healthcare
Employees: 1314
Address: 215 First Street, Cambridge, MA 02142
Phone: 617 274 4000
Leadership
- Douglas S. Ingram, President and Chief Executive Officer
- Bilal Arif, Executive Vice President, Chief Technical Operations Officer
- Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
- Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
- Ian M. Estepan, Executive Vice President, Chief Financial Officer
- Dallan Murray, Executive Vice President, Chief Customer Officer
- Alison Nasisi, Executive Vice President, Chief People Officer
- Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
- Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
- M. Kathleen Behrens, PhD, Chairwoman
- Richard J. Barry,
- Kathryn Boor, PhD,
- Michael Chambers,
- Deirdre Connelly,
- Stephen L. Mayo, PhD,
- Claude Nicaise, MD,
- Hans Wigzell, MD, PhD,
- John C. Martin, PhD (In Memoriam),
- Annemieke Aartsma-Rus, PhD,
- Carsten Bönnemann, MD,
- Joy Cavagnaro, PhD, DABT, Fellow ATS,
- Kay Davies, PhD, DBE FMedSci FRS,
- Steven Gray, PhD,
- Angela J. Russell, DPhil,
Last updated: 2024-12-31
Enzo Biochem, Inc.
Life Sciences Products
Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company specializing in the research, development, manufacture, and marketing of diagnostic and research products using genetic engineering, biotechnology, and molecular biology. It operates through segments focused on Life Sciences Products, Clinical Laboratory Services, and Therapeutics.
About | About | About | About | About | Leadership | Locations | About | About | About | About | Careers | Benefits | Careers | About | Jobs | Careers | Careers | Careers | Jobs | Jobs | Jobs | Jobs | About | About | About | About
Symbol: ENZ
Recent Price: $0.70
Industry: Medical - Diagnostics & Research
CEO: Ms. Kara Cannon
Sector: Healthcare
Employees: 125
Address: 527 Madison Avenue, New York, NY 10022
Phone: 212 583 0100
Last updated: 2024-12-31
BioMarin Pharmaceutical Inc.
Vimizim
Bio Marin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Their products cater to conditions like mucopolysaccharidosis, phenylketonuria, Batten disease, and more.
About | Leadership | Directors | About | About | About | Locations | Contact | About | Careers | Careers | Benefits | Careers | Events | Careers | Careers | Careers | Careers | Careers | Careers | Locations | Careers | Careers | Careers | Careers | Jobs | Site Map | About | About | About | About | About | About | About | About
Symbol: BMRN
Recent Price: $65.45
Industry: Biotechnology
CEO: Mr. Alexander Hardy
Sector: Healthcare
Employees: 3401
Address: 770 Lindaro Street, San Rafael, CA 94901
Phone: 415 506 6700
Leadership
- Mark Enyedy,
- Alexander Hardy,
- Elaine J. Heron,
- G. Eric Davis, Executive Vice President, Chief Legal Officer
- Greg Friberg, Executive Vice President, Chief Research & Development Officer
- C. Greg Guyer, Executive Vice President, Chief Technical Officer
- Cristin Hubbard, Executive Vice President, Chief Commercial Officer
- Marni Kottle, Executive Vice President, Chief Corporate Affairs Officer
- Brian R. Mueller, Executive Vice President, Chief Financial Officer
- James Sabry, Executive Vice President, Chief Business Officer
- Amy Wireman, Executive Vice President, Chief People Officer
- Richard A. Meier,
- Elizabeth McKee Anderson,
- Barbara Bodem,
- Athena Countouriotis,
- Willard H. Dere,
- Maykin Ho,
- Robert J. Hombach,
- David E.I. Pyott,
Last updated: 2024-12-31
Eloxx Pharmaceuticals, Inc.
ELX-02
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing ribosome modulation therapies for rare and ultra-rare premature stop codon diseases. The company's lead investigational drug, ELX-02, is in Phase 2 clinical trials for cystic fibrosis and nephropathic cystinosis.
Symbol: ELOX
Recent Price: $0.00
Industry: Biotechnology
CEO: Mr. Sumit Aggarwal M.B.A.
Sector: Healthcare
Employees: 18
Address: 480 Arsenal Way, Watertown, MA 02472
Phone: 781 577 5300
Last updated: 2024-12-31
FibroGen, Inc.
Roxadustat, Pamrevlumab
Fibro Gen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics to treat serious unmet medical needs, including treatments for anemia, idiopathic pulmonary fibrosis, and Duchenne muscular dystrophy.
Symbol: FGEN
Recent Price: $0.53
Industry: Biotechnology
CEO: Mr. Thane Wettig
Sector: Healthcare
Employees: 486
Address: 409 Illinois Street, San Francisco, CA 94158
Phone: 415 978 1200
Last updated: 2024-12-31
Inhibikase Therapeutics, Inc.
Ik T-148009
Inhibikase Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing therapeutics for Parkinson's Disease and related disorders. Their product pipeline includes treatments for neurological and cancer-related conditions.
About | Leadership | Directors | About | About | About | Contact | Careers | About | About | About | About
Symbol: IKT
Recent Price: $3.24
Industry: Biotechnology
CEO: Dr. Milton H. Werner Ph.D.
Sector: Healthcare
Employees: 8
Address: 3350 Riverwood Parkway SE, Atlanta, GA 30339
Phone: 678 392 3419
Leadership
- Milton H. Werner, Ph.D., President and CEO
- C. Warren Olanow MD, FRCPC, FRCP (Hon.), Medical Consultant and CEO of Clintrex Research Corporation
- Garth Lees-Rolfe, CPA, Chief Financial Officer
- Dan Williams, Controller
- Terence Kelly, Ph.D., Medicinal Chemistry Consultant
- Surendra Singh, Ph.D., Chemistry and Manufacturing Controls
- Merrill M. Kraines, Partner, McDermott, Will & Emery, Outside General Counsel
- Roberto Bellini, Managing Partner at BSQUARED Capital
- Dennis Berman, Serial Entrepreneur
- David Canner, Ph.D., Partner at Soleus Capital
- Roy Freeman, M.D., Professor of Neurology at the Harvard Medical School, Director of the Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center
- Arvind Kush, Chief Financial Officer and Chief Business Officer of Candid Therapeutics
- Amit Munshi, Chief Executive Officer of Orna Therapeutics
Last updated: 2024-12-31
Incyte Corporation
JAKAFI, PEMAZYRE, ICLUSIG
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.
About | Leadership | Contact | Contact | Locations | Contact | Contact | Culture | Jobs | Culture | DEI | News | Events | About | About | Careers | Jobs | Careers | Careers | DEI | Culture | Careers | Culture | DEI | Careers | Locations | Careers | About | About | About | About | About | Careers | About | About | Culture
Symbol: INCY
Recent Price: $68.42
Industry: Biotechnology
CEO: Mr. Herve Hoppenot
Sector: Healthcare
Employees: 2524
Address: 1801 Augustine Cut-Off, Wilmington, DE 19803
Phone: 302 498 6700
Leadership
- Hervé Hoppenot, Chairman and Chief Executive Officer
- Paula J. Swain, Executive Vice President, Human Resources
- Pablo J. Cagnoni, M.D., President, Head of Research and Development
- Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
- Sheila A. Denton, J.D., Executive Vice President and General Counsel
- Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
- Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
- Denise Brashear, Vice President, Head of Global Communications
- Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
- Lee Heeson, Executive Vice President, Head of Incyte International
- Michael Morrissey, Executive Vice President and Head of Global Technical Operations
- Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
- Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
- Julian C. Baker, Managing Partner
- Jean-Jacques Bienaime, Former Chief Executive Officer
- Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
- Paul J. Clancy, Former Executive Vice President and Senior Advisor
- Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
- Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
- Katherine High, M.D., Former President and Head of Research and Development
- Susanne Schaffert, Ph.D., Former President
Last updated: 2024-12-31
Inovio Pharmaceuticals, Inc.
DNA Medicines
Inovio Pharmaceuticals is a biotechnology company focused on discovering, developing, and commercializing DNA medicines to treat and protect against diseases like HPV, cancer, and infectious diseases. Their platform includes Syn Con designed DNA sequences and CELLECTRA smart devices technology for delivery.
Vision/Values | Leadership | About | Leadership | Vision/Values | About | Contact | Careers | Careers | About | About | About | About | About
Symbol: INO
Recent Price: $1.78
Industry: Biotechnology
CEO: Dr. Jacqueline E. Shea Ph.D.
Sector: Healthcare
Employees: 127
Address: 660 West Germantown Pike, Plymouth Meeting, PA 19462
Phone: 267 440 4200
Leadership
- Jacqueline Shea, Ph.D., President & Chief Executive Officer
- Peter Kies, Chief Financial Officer
- Michael Sumner, MB BS, MBA, Chief Medical Officer
- Laurent Humeau, Ph.D., Chief Scientific Officer; Chairman, Scientific Advisory Board
- Steve Egge, MBA, Chief Commercial Officer
- Rob Crotty, J.D., General Counsel and Chief Compliance Officer
- EJ Brandreth, MBA, Senior Vice President, Quality Assurance
- Shawn Bridy, MA, MBA, Senior Vice President, Business Development
- Cheryl Elder, PharmD, Senior Vice President, Regulatory Affairs
- Robert J. Juba Jr., Senior Vice President, Biological Manufacturing and Clinical Supply Management
- Jeffrey Skolnik, M.D., Senior Vice President, Clinical Development
- Dave Liebowitz, M.D. & Ph.D., Senior Vice President, Early-Stage Clinical Development
- Simon X. Benito, Chairman of the Board, Inovio Pharmaceuticals
- Roger D. Dansey, M.D., Chief Medical Officer at Seagen
- Ann C. Miller, M.D., Former Head of Sanofi Oncology Global Marketing
- Jay Shepard, Former President & CEO of Aravive
- David B. Weiner, Ph.D., Executive Vice President, Director, Vaccine Center, The Wistar Institute
- Wendy L. Yarno, MBA, Former Executive Vice President and Chief Marketing Officer at Merck & Co., Inc.
- Lota S. Zoth, CPA, Former Chief Financial Officer, MedImmune
- Rafi Ahmed, Ph.D., Director, Emory Vaccine Center, Emory University School of Medicine
- Stanley A. Plotkin, M.D., Emeritus Professor, Wistar Institute and University of Pennsylvania; Principal, Vaxconsult
Last updated: 2024-12-31
Inozyme Pharma, Inc.
INZ-701
Inozyme Pharma, Inc. is a biopharmaceutical company focused on the development of therapeutics for rare disease conditions involving abnormal mineralization, particularly targeting ENPP1 and ABCC6 deficiencies.
Symbol: INZY
Recent Price: $2.82
Industry: Biotechnology
CEO: Dr. Douglas A. Treco Ph.D.
Sector: Healthcare
Employees: 59
Address: 321 Summer Street, Boston, MA 02210
Phone: 857 330 4340
Leadership
- Doug Treco, Ph.D., CEO, Chairman of Board of Directors
- Gayle Gironda, Senior Vice President and Chief People Officer
- Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer
- Soojin Kim, Ph.D., Senior Vice President and Chief Technical Operations Officer
- Yves Sabbagh, Ph.D., Senior Vice President and Chief Scientific Officer, Chair of the Scientific Advisory Board
- Sanjay S. Subramanian, M.S., MBA, Senior Vice President and Chief Financial Officer
- Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer
- Axel Bolte, MBA, Co-founder, Senior Advisor and Member of Board of Directors
- David Thompson, M.A., M.S., Ph.D., Senior Advisor, Member of Scientific Advisory Board
- Sarah Bhagat, Ph.D., Director
- Reinaldo M. Diaz, MBA, Director
- Martin Edwards M.D., MBA, Director
- Erik Harris, MBA, Director
- Rob Hopfner, Rph, Ph.D., MBA, Director
- Edward Mathers, Director
- Lynne Sullivan, MST, Director
Last updated: 2024-12-31
Quince Therapeutics, Inc.
NOV004
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases, with a bone-targeting drug platform and lead compound NOV004 designed to target bone fracture and disease sites.
Symbol: QNCX
Recent Price: $1.85
Industry: Biotechnology
CEO: Dr. Dirk Thye M.D.
Sector: Healthcare
Employees: 32
Address: 601 Gateway Blvd, South San Francisco, CA 94080
Phone: 415 910 5717
Last updated: 2024-12-31
Rocket Pharmaceuticals, Inc.
Gene Therapies
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with multiple clinical-stage programs targeting disorders such as fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and Danon disease.
Symbol: RCKT
Recent Price: $12.03
Industry: Biotechnology
CEO: Dr. Gaurav D. Shah M.D.
Sector: Healthcare
Employees: 268
Address: 9 Cedarbrook Drive, Cranbury, NJ 08512
Phone: 609 659 8001
Last updated: 2024-12-31
Abeona Therapeutics Inc.
EB-101
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.
Symbol: ABEO
Recent Price: $5.61
Industry: Biotechnology
CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.
Sector: Healthcare
Employees: 84
Address: 1330 Avenue of the Americas, New York, NY 10019
Phone: 646 813 4701
Last updated: 2024-12-31
IN8bio, Inc.
INB-200, INB-100, INB-400, INB-300
IN8bio, Inc. is a clinical-stage biotechnology company focused on gamma-delta T cell therapies for cancer treatment, with lead products in clinical trials and preclinical development.
Symbol: INAB
Recent Price: $0.27
Industry: Biotechnology
CEO: Mr. Tai-Wei Ho
Sector: Healthcare
Employees: 39
Address: 350 5th Avenue, New York, NY 10118
Phone: 646 600 6438
Last updated: 2024-12-31